New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2014
11:51 EDTAKAM, ISRG, CMG, SNDK, AZNOptions with increasing implied volatility: AKAM ISRG CMG SNDK AZN
News For AKAM;ISRG;CMG;SNDK;AZN From The Last 14 Days
Check below for free stories on AKAM;ISRG;CMG;SNDK;AZN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
August 26, 2014
16:22 EDTAKAMAkamaiinitiated with an Outperform at RW Baird
Target $71.
07:22 EDTISRGISI Group to hold a field trip
Subscribe for More Information
06:09 EDTSNDKStocks with implied volatility below IV index mean; SNDK WAG
Subscribe for More Information
August 25, 2014
07:32 EDTCMGMcDonald's challenged as younger eaters defect to Chipotle, WSJ says
As McDonald's (MCD) faces a prolonged slump in sales growth, data compiled for The Wall Street Journal by Technomic showed that diners in their 20s and 30s are seeking out fresher, healthier food and defecting to competitors, in particular fast-casual restaurants like Chipotle Mexican Grill (CMG) and higher-end burger chain Five Guys. Reference Link
06:29 EDTAZNPfizer mulls possible AstraZeneca offer options, FT says
Subscribe for More Information
06:15 EDTSNDKStocks with implied volatility below IV index mean; SNDK WAG
Subscribe for More Information
August 24, 2014
21:56 EDTAKAMB. Riley to hold a tour
Silicon Valley Tech Tour travels throughout Silicon Valley on August 25-27.
August 22, 2014
10:07 EDTAZNOptions with increasing implied volatility: ORPH EXAS AZN
Subscribe for More Information
05:44 EDTSNDKStocks with implied volatility below IV index mean; SNDK WAG
Stocks with implied volatility below IV index mean; SanDisk (SNDK) 23, Walgreen (WAG) 20 according to iVolatility.
05:19 EDTAZNStocks with implied volatility movement; JRJC AZN
Subscribe for More Information
August 21, 2014
13:00 EDTISRGIntuitive Surgical receives FireFly FDA clearance for Vinci Xi system
Subscribe for More Information
09:54 EDTAZNPotential Pfizer, AstraZeneca deal seen around year-end, Reuters says
Investors and analysts see Pfizer (PFE) making another attempt to acquire AstraZeneca (AZN) around year-end, even though talks between the two can resume on August 26 per British takeover rules, Reuters reports. Reference Link
09:03 EDTCMGChipotle Q3 comps accelerating, says Cleveland Research
Subscribe for More Information
08:49 EDTSNDKSanDisk gross margins to get boost from FIO, says Sterne Agee
Sterne Agee expects SanDisk's gross margins to be boosted from the integration of the FIO Enterprise SSD unit, whose acquisition closed on July 23. The firm adds that the company's new Malaysia factory should drive its tax rate lower over time. Sterne Agee keeps a $125 price target and Buy rating on the shares.
07:47 EDTAZNPfizer looking at new targets, including Actavis, Bloomberg reports
While it weighs another attempt to acquire AstraZeneca (AZN), Pfizer is considering other overseas alternatives, including Actavis (ACT), Bloomberg reports, citing people familiar with the matter. Pfizer prefers to reach a deal with AstraZeneca, and a move on another company is unlikely "anytime soon," Bloomberg adds, citing its sources. Shares of Actavis are rising 3%, or $6.65, to $230.01 in pre-market trading, while AstraZeneca is up 2% to $72.59. Reference Link
06:12 EDTSNDKDRAM prices making downward correction with oversupply concerns, DigiTimes says
Subscribe for More Information
05:50 EDTSNDKStocks with implied volatility movement; QCOM SNDK
Subscribe for More Information
05:42 EDTAZNIllumina announces strategic partnership with AstraZeneca, Sanofi, Janssen
Illumina (ILMN) announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing, or NGS,-based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine. Initial strategic partners include AstraZeneca (AZN), Janssen Biotech, a Johnson & Johnson (JNJ) company, and Sanofi (SNY). Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners’ clinical trials, with the objectives of securing regulatory agency approvals and test commercialization. In parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm. Together, Illumina and its strategic partners aim to transition from single-analyte companion diagnostics to panel-based assays that select for “companion therapeutics.”
August 19, 2014
07:01 EDTAZNDOJ closes investigation into PLATO Brilinta clinical trial, plans no action
AstraZeneca today announced that it has received confirmation from the United States Department of Justice that it is closing its investigation into PLATO, a clinical trial with BRILINTA tablets. The government is not planning any further action. Pascal Soriot, CEO, said: “We welcome the Department of Justice’s decision not to pursue further action. We have always had absolute confidence in the integrity of the PLATO trial and we are proud of the important benefit BRILINTA offers to patients around the world suffering from acute coronary syndrome. As one of AstraZeneca’s growth platforms, we remain committed to delivering the full potential of this important medicine.” As part of our continued commitment to advancing the science behind cardiovascular medicine, AstraZeneca has initiated a clinical trial program for BRILINTA, its largest program involving more than 80,000 patients worldwide.
August 18, 2014
07:57 EDTAZNCambridge Healthtech Institute to hold a summit
6th Annual Bioprocessing Summit to be held in Boston on August 18-22.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use